AstraZeneca Says Breztri Improves Lung Function, Reduces Attacks in Phase 3 Asthma Trials

MT Newswires Live02-13

AstraZeneca (AZN) said Friday that pooled results from its phase 3 Kalos and Logos trials showed Breztri improved lung function by up to 90mL compared with Symbicort and other dual-combination steroid inhalers.

The analysis of 4,300 patients with uncontrolled asthma demonstrated that the triple-therapy also reduced the rate of severe attacks versus the standard budesonide and formoterol treatment, the company said.

No new safety or tolerability signals were identified in the studies, which tested the medicine against current therapeutic options over a period of 24 to 52 weeks, AstraZeneca said.

The company also said the treatment is already authorized in over 80 countries for chronic obstructive pulmonary disease, while filings for its use in asthma are currently under review in all major regions.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2611132847?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-13 16:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2611132847","market":"fut","top_or_hot":-1,"title":"AstraZeneca Says Breztri Improves Lung Function, Reduces Attacks in Phase 3 Asthma Trials","media":"MT Newswires Live","content":"<html><body><p> AstraZeneca (AZN) said Friday that pooled results from its phase 3 Kalos and Logos trials showed Breztri improved lung function by up to 90mL compared with Symbicort and other dual-combination steroid inhalers.</p><p>The analysis of 4,300 patients with uncontrolled asthma demonstrated that the triple-therapy also reduced the rate of severe attacks versus the standard budesonide and formoterol treatment, the company said.</p><p>No new safety or tolerability signals were identified in the studies, which tested the medicine against current therapeutic options over a period of 24 to 52 weeks, AstraZeneca said.</p><p>The company also said the treatment is already authorized in over 80 countries for chronic obstructive pulmonary disease, while filings for its use in asthma are currently under review in all major regions.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca Says Breztri Improves Lung Function, Reduces Attacks in Phase 3 Asthma Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca Says Breztri Improves Lung Function, Reduces Attacks in Phase 3 Asthma Trials\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-02-13 16:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> AstraZeneca (AZN) said Friday that pooled results from its phase 3 Kalos and Logos trials showed Breztri improved lung function by up to 90mL compared with Symbicort and other dual-combination steroid inhalers.</p><p>The analysis of 4,300 patients with uncontrolled asthma demonstrated that the triple-therapy also reduced the rate of severe attacks versus the standard budesonide and formoterol treatment, the company said.</p><p>No new safety or tolerability signals were identified in the studies, which tested the medicine against current therapeutic options over a period of 24 to 52 weeks, AstraZeneca said.</p><p>The company also said the treatment is already authorized in over 80 countries for chronic obstructive pulmonary disease, while filings for its use in asthma are currently under review in all major regions.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2417539215.USD","symbol_name":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2611132847","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2611132847","pubTimestamp":1770972868,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"AstraZeneca  said Friday that pooled results from its phase 3 Kalos and Logos trials showed Breztri improved lung function by up to 90mL compared with Symbicort and other dual-combination steroid inhalers.The analysis of 4,300 patients with uncontrolled asthma demonstrated that the triple-therapy also reduced the rate of severe attacks versus the standard budesonide and formoterol treatment, the company said.No new safety or tolerability signals were identified in the studies, which tested the medicine against current therapeutic options over a period of 24 to 52 weeks, AstraZeneca said.The company also said the treatment is already authorized in over 80 countries for chronic obstructive pulmonary disease, while filings for its use in asthma are currently under review in all major regions.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4007":"制药","AZN":"阿斯利康","LU0058720904.USD":"联博国际健康护理基金A","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1829250122.USD":"高盛欧洲核心股票组合Acc","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","BK4588":"碎股","BK4568":"美国抗疫概念","BK4585":"ETF&股票定投概念","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)"},"translate_title":"阿斯利康表示Breztri在3期哮喘试验中可改善肺功能并减少发作","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":1},"content_text":"AstraZeneca (AZN) said Friday that pooled results from its phase 3 Kalos and Logos trials showed Breztri improved lung function by up to 90mL compared with Symbicort and other dual-combination steroid inhalers.The analysis of 4,300 patients with uncontrolled asthma demonstrated that the triple-therapy also reduced the rate of severe attacks versus the standard budesonide and formoterol treatment, the company said.No new safety or tolerability signals were identified in the studies, which tested the medicine against current therapeutic options over a period of 24 to 52 weeks, AstraZeneca said.The company also said the treatment is already authorized in over 80 countries for chronic obstructive pulmonary disease, while filings for its use in asthma are currently under review in all major regions.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2611132847","isCrawlerRequest":true}